Table 3.
Outcomes in Americas according to the presence/absence of RHTN
| RHTN | No RHTN | P for interaction between RHTN and no RHTN and treatmenta | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number and % of participants with events, and incidence rate per 100 person-year | Unadjusted model HR, 95% CI, P value | Strata modelb HR, 95% CI, P value | Adjusted modelc HR, 95% CI, P value | Number and % of participants with events, and incidence rate per 100 person-year | Unadjusted model HR, 95% CI, P value | Strata modelb HR, 95% CI, P value | Adjusted modelc HR, 95% CI, P value | ||||
| Primary | 70 (33.0%), 13.8 per 100 pyr | 48 (25.3%), 9.6 per 100 pyr | 70 (33.0%), 13.8 per 100 pyr | 48 (25.3%), 9.6 per 100 pyr | 0.70 (0.49– 1.01), 0.06 | 210 (31.5%), 12.3 per 100 pyr | 194 (28.0%), 10.6 per 100 pyr | 0.86 (0.71–1.05), 0.14 | 0.84 (0.69– 1.02), 0.08 | 0.83 (0.68– 1.01), 0.057 | 0.53 |
| CVD | 29 (16.7%), 4.8 per 100 pyr | 18 (9.5%), 3.2 per 100 pyr | 0.67 (0.37–1.21), 0.19 | 0.71 (0.39– 1.28), 0.26 | 0.68 (0.37– 1.23), 0.20 | 98 (14.7%), 4.9 per 100 pyr | 78 (11.2%), 3.8 per 100 pyr | 0.76 (0.56–1.02), 0.07 | 0.75 (0.56– 1.01), 0.057 | 0.74 (0.55– 0.99), 0.045 | 0.71 |
| HF hospitalization | 57 (26.9%), 11.2 per 100 pyr | 40 (21.1%), 8.0 per 100 pyr | 0.72 (0.48–1.07), 0.11 | 0.74 (0.49– 1.11), 0.15 | 0.75 (0.50– 1.13), 0.16 | 159 (23.8%), 9.3 per 100 pyr | 144 (20.8%), 7.9 per 100 pyr | 0.85 (0.68–1.07), 0.16 | 0.83 (0.66– 1.04), 0.10 | 0.81 (0.65– 1.02), 0.075 | 0.45 |
| Recurrent HF | 19.4 per 100 pyr | 14.1 per 100 pyr | 0.57 (0.35–0.95), 0.029 | 0.57 (0.34– 0.93), 0.026 | 0.63 (0.38– 1.05), 0.08 | 16.2 per 100 pyr | 13.6 per 100 pyr | 0.82 (0.61–1.10), 0.18 | 0.76 (0.57– 1.01), 0.059 | 0.74 (0.56– 0.98), 0.037 | 0.22 |
| All cause mortality | 41 (19.3%), 6.4 per 100 pyr | 30 (15.8%), 5.0 per 100 pyr | 0.78 (0.48–1.24), 0.29 | 0.80 (0.50– 1.28), 0.34 | 0.72 (0.44– 1.16), 0.18 | 166 (24.9%), 8.1 per 100 pyr | 147 (21.2%), 6.8 per 100 pyr | 0.83 (0.67–1.04), 0.11 | 0.83 (0.66– 1.03), 0.09 | 0.80 (0.64– 1.01), 0.056 | 0.80 |
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CI, confidence interval; CVD, cardiovascular death; HF: heart failure; HR, hazard ratio; RHTN, resistant hypertension.
aFrom unadjusted model.
bStratified by eligibility strata.
cFurther adjusted for age, ACE/ARB, diabetes.